TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
Recruiting
Observational Study
Hepatocellular Carcinoma (HCC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 120 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research aims to evaluate the safety, clinical efficacy and prognostic factors of TACE and/or HAIC combined with targeted immuno…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* aged 18-80 years
* Eastern Cooperative Oncology Group (ECOG) performance status score \< 2
* maximum tumor diameter ≥ 7 cm
* IVC/RA TT diagnosed by contrast-enhanced CT / MRI before study treatment
* unresectable HCC (uHCC) confirmed by a specialized multidisciplinary team
* l…
Contacts
No contact information available.